Positron emission tomography (PET) using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (18F-FDG) combined with computed tomography (CT) represents a three-dimensional imaging method suitable for staging in patients with non-Hodgkin's lymphomas (NHLs). The aim of our prospective multicenter study was to assess the value of initial PET/CT as compared with CT and PET alone for determining the stage and extent of the disease. A total of 122 patients with newly diagnosed NHL were examined using PET/CT. Four patients with resected lymphoma lesion and negative PET/CT were therefore excluded from the study. Of the remaining 118 cases, a total of 117 (99%) were described as 18F-FDG-avid. When compared with PET/CT, CT and PET showed very good sensitivity of lymph node imaging (97% and 100%, respectively); the specificity, however, was significantly lower (66.7% and 94.4%, respectively; p=0.0001). When detecting organ lesions, the sensitivity of CT and PET was lower than that of PET/CT (92.5% and 96.3%, respectively; p=0.0001); specificity was significantly decreased in CT and a little lower in PET (59.5% and 91.9%; p=0.0001). When compared with CT alone, PET/CT changed staging of the disease in 11 patients (9%) and was able to detect a total of 82 discrepancies in 67 of the 117 patients (57%). In conclusion, PET/CT is a new standard in imaging the involvement of lymph nodes and extranodal organs in NHL patients regardless of their histopathological types. Both sensitivity and specificity of the examination are higher than those of CT as well as PET alone.

Department of Hemato Oncology University Hospital Olomouc and Faculty of Medicine and Dentistry Palacky University 1 P Pavlova Olomouc Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc12027582

003      

CZ-PrNML

005      

20140730120018.0

007      

ta

008      

120817s2011 xo f 000 0#eng||

009      

AR

024    7_

$a 10.4149/neo_2011_04_291 $2 doi

035    __

$a (PubMed)21524147

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xo

100    1_

$a Papajík, Tomáš, $d 1967- $7 xx0060566 $u Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University I.P.Pavlova Olomouc, Czech Republic. tomas.papajik@fnol.cz

245    10

$a Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin's lymphoma using 18F-FDG-PET/CT / $c T. Papajik, M. Myslivecek, M. Skopalova, A. Malan, E. Buriankova, V. Koza, M. Hnatkova, M. Trneny, Z. Sedova, Z. Kubova, P. Koranda, P. Flodr, J. Jarkovsky, L. Dusek, K. Indrak

520    9_

$a Positron emission tomography (PET) using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (18F-FDG) combined with computed tomography (CT) represents a three-dimensional imaging method suitable for staging in patients with non-Hodgkin's lymphomas (NHLs). The aim of our prospective multicenter study was to assess the value of initial PET/CT as compared with CT and PET alone for determining the stage and extent of the disease. A total of 122 patients with newly diagnosed NHL were examined using PET/CT. Four patients with resected lymphoma lesion and negative PET/CT were therefore excluded from the study. Of the remaining 118 cases, a total of 117 (99%) were described as 18F-FDG-avid. When compared with PET/CT, CT and PET showed very good sensitivity of lymph node imaging (97% and 100%, respectively); the specificity, however, was significantly lower (66.7% and 94.4%, respectively; p=0.0001). When detecting organ lesions, the sensitivity of CT and PET was lower than that of PET/CT (92.5% and 96.3%, respectively; p=0.0001); specificity was significantly decreased in CT and a little lower in PET (59.5% and 91.9%; p=0.0001). When compared with CT alone, PET/CT changed staging of the disease in 11 patients (9%) and was able to detect a total of 82 discrepancies in 67 of the 117 patients (57%). In conclusion, PET/CT is a new standard in imaging the involvement of lymph nodes and extranodal organs in NHL patients regardless of their histopathological types. Both sensitivity and specificity of the examination are higher than those of CT as well as PET alone.

650    _2

$a fluorodeoxyglukosa F18 $x diagnostické užití $7 D019788

650    _2

$a lidé $7 D006801

650    _2

$a nehodgkinský lymfom $x patologie $x radioizotopová diagnostika $7 D008228

650    _2

$a staging nádorů $x metody $7 D009367

650    _2

$a pozitronová emisní tomografie $7 D049268

650    _2

$a radiofarmaka $x diagnostické užití $7 D019275

650    _2

$a senzitivita a specificita $7 D012680

650    _2

$a počítačová rentgenová tomografie $7 D014057

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Mysliveček, Miroslav, $d 1946- $7 jn20000401824

700    1_

$a Skopalova, M

700    1_

$a Malan, A

700    1_

$a Buriankova, E

700    1_

$a Koza, V

700    1_

$a Hnatkova, M

700    1_

$a Trněný, Marek, $d 1960- $7 nlk20000083659

700    1#

$a Šedová, Zuzana. $7 xx0216491

700    1#

$a Kubová, Zuzana. $7 xx0199107

700    1_

$a Koranda, Pavel, $d 1957- $7 ola2003193656

700    1_

$a Flodr, Patrik, $d 1975- $7 nlk20030127444

700    1_

$a Jarkovský, Jiří $7 stk2008461294

700    1_

$a Dušek, Ladislav, $d 1967- $7 mzk2003181727

700    1_

$a Indrák, Karel, $d 1947- $7 jn20000401162

773    0_

$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 58, č. 4 (2011), s. 291-7

856    41

$u https://pubmed.ncbi.nlm.nih.gov/21524147 $y Pubmed

910    __

$a ABA008 $b A 1194 $c 659 $y m $z 0

990    __

$a 20120817 $b ABA008

991    __

$a 20140730120336 $b ABA008

999    __

$a ok $b bmc $g 949624 $s 784928

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2011 $b 58 $c 4 $d 291-7 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470

LZP    __

$a Pubmed-20120817/11/03